Nomura Securities Maintains a 'Buy' on Shire plc (SHPGY); FDA Approved Generic Version of Adderall-XR

Nomura Securities maintains a 'Buy' on Shire plc (NASDAQ: SHPGY).

Analyst, Bhuna Signhal, said, "The FDA has approved a generic version of Adderall-XR (10% of EPS). The EMA has rejected Pfizer’s Taliglucerase, a potential competitor to Shire’s Vpriv (10% of EPS). We had previously flagged that (given the FDA’s recent approval of a generic version of another ADHD drug) Adderall-XR will go generic and had removed the drug from our model. Therefore, the FDA news makes little change to our 11% EPS CAGR forecast for Shire. We do, however, make changes to reflect possible earlier onset of sales erosion than previously anticipated and lower 2012-14E EPS by 3-8%."

For an analyst ratings summary and ratings history on Shire plc click here. For more ratings news on Shire plc click here.

Shares of Shire plc closed at $91.36 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• UBS Reiterates Buy Rating on HF Sinclair (DINO)